The effects of extensive grazing on the vegetation of a landscape-scale restoration site

The Wicken Fen Vision (Cambridgeshire, UK) is a landscape-scale habitat restoration project that uses process-driven, open-ended approaches to develop habitats on highly degraded and drained peat soils of former intensive arable land. The project land is extensively grazed with herds of free-roaming, minimally managed herds of Highland cattle and Konik horses. In one 119 ha area, seven 25m x 25 m grazing exclosures were erected and vascular plant species were recorded from 2007 to 2017. Plant species data were analysed to (1) compare changes in plant species composition and diversity in grazed and ungrazed areas; (2) use plant species traits and plant-environment associations to explore the nature of changes in plant composition; (3) use remote sensing to explore changes in vegetation structure; (4) examine the influence of land use histories on grazing outcomes in different parts of the site. There was a clear divergence through time between grazed and ungrazed areas, attributed to significantly greater canopy height, Ellenberg L (Light) and Ellenberg N (fertility) values within the exclosures. Species richness was significantly higher in grazed compared with ungrazed areas and species assemblages separated through the study period. After ten years, extensive free-roaming grazing has had significant impacts on vegetation structure and species richness but effects varied across the study site because of differing historical land use

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

BACKGROUND: A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. METHODS: In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients with advanced or metastatic NSCLC with a confirmed MET exon 14 skipping mutation. The primary end point was the objective response by independent review among patients who had undergone at least 9 months of follow-up. The response was also analyzed according to whether the presence of a MET exon 14 skipping mutation was detected on liquid biopsy or tissue biopsy. RESULTS: As of January 1, 2020, a total of 152 patients had received tepotinib, and 99 patients had been followed for at least 9 months. The response rate by independent review was 46% (95% confidence interval [CI], 36 to 57), with a median duration of response of 11.1 months (95% CI, 7.2 to could not be estimated) in the combined-biopsy group. The response rate was 48% (95% CI, 36 to 61) among 66 patients in the liquid-biopsy group and 50% (95% CI, 37 to 63) among 60 patients in the tissue-biopsy group; 27 patients had positive results according to both methods. The investigator-assessed response rate was 56% (95% CI, 45 to 66) and was similar regardless of the previous therapy received for advanced or metastatic disease. Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. Adverse events led to permanent discontinuation of tepotinib in 11% of the patients. A molecular response, as measured in circulating free DNA, was observed in 67% of the patients with matched liquid-biopsy samples at baseline and during treatment. CONCLUSIONS: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients. Peripheral edema was the main toxic effect of grade 3 or higher. (Funded by Merck [Darmstadt, Germany]; VISION ClinicalTrials.gov number, NCT02864992.)

A Perspective of International Collaboration Through Web-Based Telecommunication–Inspired by COVID-19 Crisis

The tsunami effect of the COVID-19 pandemic is affecting many aspects of scientific activities. Multidisciplinary experimental studies with international collaborators are hindered by the closing of the national borders, logistic issues due to lockdown, quarantine restrictions, and social distancing requirements. The full impact of this crisis on science is not clear yet, but the above-mentioned issues have most certainly restrained academic research activities. Sharing innovative solutions between researchers is in high demand in this situation. The aim of this paper is to share our successful practice of using web-based communication and remote control software for real-time long-distance control of brain stimulation. This solution may guide and encourage researchers to cope with restrictions and has the potential to help expanding international collaborations by lowering travel time and costs